Research progress of PARP inhibitors in cancers and their drug resistance
10.11665/j.issn.1000-5048.20220503
- VernacularTitle:PARP抑制剂在恶性肿瘤中的应用及耐药研究进展
- Author:
Wanwan YANG
1
;
Fangyu YE
;
Yujia WU
;
Haochen WANG
;
Li ZHAO
Author Information
1. 中国药科大学基础医学与临床药学学院
- Publication Type:Journal Article
- Keywords:
PARP inhibitor;
antitumor;
drug resistance;
drug combination;
progress
- From:
Journal of China Pharmaceutical University
2022;53(5):525-534
- CountryChina
- Language:Chinese
-
Abstract:
Poly ADP-ribose polymerase-1 (PARP-1) plays a vital role in organisms, including regulating repair of DNA, maintaining genome stability, regulating cell proliferation, differentiation, and death.At present, PARP inhibitors have been made some breakthrough in the treatment of breast cancer, ovarian cancer, prostate cancer and pancreatic cancer.However, PARP inhibitors have certain limitations in other malignant tumors and patients who are resistant to PARP-1 inhibitors.This article summarizes the research on PARP inhibitors in lung cancer, hepatocellular carcinoma, glioblastoma, leukemia and cervical cancer, and introduces the strategies of combining other anti-tumor drugs such as DNA repair inhibitors, immune checkpoint inhibitors, anti-angiogenic drugs and other chemotherapeutic drugs to solve their drug resistance, which provides some reference for the wide clinical application of PARP inhibitors in the future.
